Effects of phenoxybenzamine hydrochloride on canine lower urinary tract Clinical implications

Khanna, Om P.; Guglielmi, Paul

doi:10.1016/0090-4295(75)90756-6

Cited by 49 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, targeting a 1 ARs by speci¢c antagonists causes a decrease in the ureteral peristaltic amplitude and frequency, with a reduction in intraureteral pressure and £uid transport volume [Morita et al, 1987a,b]. A role of ARs in the ureter contraction and the positive e¡ect of adrenergic blockade in the treatment of ureteral colic was suggested by Khanna and Gonick [1977], and Kubacz and Catchpole [1972]. These studies demonstrated that mixed a 1/2 adrenergic antagonists reduce the ureteral pressure and, in particular, phentolamine is e¡ective in relieving pain in patients with ureteral colic [Kubacz and Catchpole, 1972].…”

Section: Discussionmentioning

confidence: 97%

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

Sigala

Dellabella

Milanese

et al. 2005

Neurourology and Urodynamics

169

View full text Add to dashboard Cite

Human ureter was endowed with each alpha1 AR subtype, although alpha1D and alpha1A ARs were prevalent over alpha1B ARs. Radioligand binding results revealed that there were no significant differences in the K(d) between ureteral regions, while a heterogeneous distribution of alpha1 AR binding sites was detected, with the highest density of alpha1 ARs in the distal ureter and a lower similar density in the medial and proximal ureters.

show abstract

Section: Discussionmentioning

confidence: 97%

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

Sigala

Dellabella

Milanese

et al. 2005

Neurourology and Urodynamics

169

View full text Add to dashboard Cite

show abstract

“…Thus, improvements in IPSS and urinary flow rates were considered greater in the combination group than in the other two groups. It may be reasonable to use a combination therapy with a cholinergic drug and an α‐blocker because intravesical pressure would be enhanced and urethral resistance reduced during voiding 22,23 . This seems to rationalize the use of these two different drugs in combination to treat voiding dysfunction in patients with underactive bladder.…”

Section: Discussionmentioning

confidence: 99%

Combination of a cholinergic drug and an α‐blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor

et al. 2004

View full text Add to dashboard Cite

Aim: The aim of the present study was to compare the effectiveness of a cholinergic drug, an ablocker and combinations of the two for the treatment of underactive detrusor. Methods: One hundred and nineteen patients with underactive bladder were assigned to three groups: the cholinergic group, consisting of 40 patients taking bethanechol chloride (60 mg/day) or distigmine bromide (15 mg/day); the a-blocker group, consisting of 38 patients taking urapidil (60 mg/ day); and the combination group, consisting of 41 patients taking both a cholinergic drug and an ablocker. The effectiveness of each therapy was assessed 4 weeks after initialization of the therapy. Results: Total urinary symptom scores (International Prostate Symptom Score, IPSS) remained unchanged after the cholinergic therapy, but were significantly lower after the a-blocker treatment (P = 0.0001) and the combination therapy (P = 0.0001). With regard to the total IPSS, there were significant differences between the cholinergic and the a-blocker groups (P = 0.0008), and also between the cholinergic and combination groups (P = 0.0033), in favor of the latter. The average and maximum flow rates did not increase significantly after monotherapy with either the cholinergic drug or the a-blocker, but they significantly increased after combination therapy compared to baseline values (P = 0.0033 and P = 0.0004, respectively). Postvoid residual volume did not decrease significantly after the cholinergic drug therapy, but decreased significantly after the a-blocker (P = 0.0043) and the combination therapies (P = 0.0008). The percentage of residual urine decreased significantly after therapy in all groups (P = 0.0005, P = 0.0176 and P = 0.0001, respectively). Conclusion: Combination therapy with a cholinergic drug and an a-blocker appears to be more useful than monotherapy for the treatment of underactive detrusor.

show abstract

“…In patients with upper motor neuron lesions, α-blockers improve uninhibited contraction [11]and/or detrusor sphincter dyssynergia [11, 12]resulting in improvement in both storage and voiding symptoms. However, at present, anticholinergics are used as the first-line medical treatment for uninhibited contraction while α-blockers are occasionally used in combination with anticholinergics to treat uninhibited contraction associated with emptying difficulties.…”

Section: Discussionmentioning

confidence: 99%

A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an α-Blocker, on Neurogenic Bladder Dysfunction

et al. 1999

View full text Add to dashboard Cite

Effects of phenoxybenzamine hydrochloride on canine lower urinary tract Clinical implications

Cited by 49 publications

References 23 publications

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

Combination of a cholinergic drug and an α‐blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor

A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an α-Blocker, on Neurogenic Bladder Dysfunction

Contact Info

Product

Resources

About

Effects of phenoxybenzamine hydrochloride on canine lower urinary tract Clinical implications

Cited by 49 publications

References 23 publications

Evidence for the presence of α1 adrenoceptor subtypes in the human ureter

Evidence for the presence of α1 adrenoceptor subtypes in the human ureter

Combination of a cholinergic drug and an α‐blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor

A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an &alpha;-Blocker, on Neurogenic Bladder Dysfunction

Contact Info

Product

Resources

About

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

Evidence for the presence of α₁ adrenoceptor subtypes in the human ureter

A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an α-Blocker, on Neurogenic Bladder Dysfunction